Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

Amgen (AMGN) closed at $295.18 in the latest trading session, marking a -1.73% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.33%. Elsewhere, the Dow saw a ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

In the last year, many Amgen Inc. (NASDAQ:AMGN) insiders sold a substantial stake in the company which may have sparked ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

The idea for Amgen’s first foray into documentary film started with two numbers, according to Nerissa Gomes, general manager ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite ...